𝔖 Bobbio Scriptorium
✦   LIBER   ✦

N-methylnitrosourea—lnduced Ki-ras codon 12 mutations: Early events in mouse thymic lymphomas

✍ Scribed by Elizabeth W. Newcomb; William Bayona; Sobha Pisharody


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
700 KB
Volume
13
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

N‐Methylnitrosourea (NMU)—induced codon 12 Ki‐ras mutations were analyzed in premalignant thymic lymphomas from C57BL/6J mice by using a selective polymerase chain reaction amplification strategy. The frequency of codon 12 Ki‐ras mutations was 67% (16 of 24) in NMU‐treated animals with premalignant stage I disease. Previously, animals with different stages of disease had been analyzed for cytogenetic changes and for mutations in the p53 tumor suppressor gene. The genetic changes observed were early‐activating codon 12 G^35^→A transition mutations of the Ki‐ras gene, followed closely by trisomy 15 and infrequent mutation of the p53 gene late in tumor development. The consistent and early detection of Ki‐ras mutations in NMU‐treated animals but not in untreated controls suggests that the mutations result from direct carcinogen exposure. Alternate pathways of NMU‐induced thymic lymphomagenesis were implicated. One pathway involved putative NMU‐induced mutations in other, non‐ras oncogenes that cooperate with trisomy 15 to produce similar T‐cell tumors. The frequency of p53 gene mutations in human and murine T‐cell tumors is similar but low. © 1995 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Frequent codon 12 Ki-ras mutations in mo
✍ Ishtiaq Rehman; David T. Lowry; Cameron Adams; Rana Abdel-Fattah; Alesia Holly; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

The skin tumor initiators N-methy-N H -nitro-N-nitrosoguanidine (MNNG) and 7,12-dimethylbenz[a]anthracene (DMBA) differ in effectiveness when tumor formation is promoted by 12-O-tetradecanoylphorbol-13-acetate (TPA). Even at high doses, MNNG is less effective, producing fewer benign and malignant tu